Perspective Therapeutics (CATX) Gains from Investment Securities (2016 - 2026)

Perspective Therapeutics' Gains from Investment Securities history spans 15 years, with the latest figure at -$78000.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 43.48% to -$78000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $60000.0, a 100.0% decrease, with the full-year FY2025 number at $10.5 million, up 43.12% from a year prior.
  • Gains from Investment Securities hit -$78000.0 in Q1 2026 for Perspective Therapeutics, down from $236000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CATX hit a ceiling of $2.0 billion in Q4 2024 and a floor of -$645000.0 in Q2 2022.
  • Historically, Gains from Investment Securities has averaged $187.0 million across 5 years, with a median of -$6500.0 in 2022.
  • Biggest five-year swings in Gains from Investment Securities: skyrocketed 1382900.0% in 2023 and later crashed 360.0% in 2025.
  • Tracing CATX's Gains from Investment Securities over 5 years: stood at $150000.0 in 2022, then surged by 406314.67% to $609.6 million in 2023, then skyrocketed by 227.24% to $2.0 billion in 2024, then crashed by 99.99% to $236000.0 in 2025, then plummeted by 133.05% to -$78000.0 in 2026.
  • Business Quant data shows Gains from Investment Securities for CATX at -$78000.0 in Q1 2026, $236000.0 in Q4 2025, and -$14000.0 in Q3 2025.